Laurie Olson Net Worth

The estimated Net Worth of Laurie J Olson is at least $6.52 Milion dollars as of 14 May 2024. Ms. Olson owns over 1,500 units of Karuna Therapeutics Inc stock worth over $4,531,205 and over the last 12 years she sold KRTX stock worth over $1,993,257. In addition, she makes $0 as Director at Karuna Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms. Olson KRTX stock SEC Form 4 insiders trading

Laurie has made over 30 trades of the Karuna Therapeutics Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently she sold 1,500 units of KRTX stock worth $25,470 on 14 May 2024.

The largest trade she's ever made was exercising 38,546 units of Karuna Therapeutics Inc stock on 28 February 2018 worth over $1,055,004. On average, Laurie trades about 4,806 units every 58 days since 2012. As of 14 May 2024 she still owns at least 13,738 units of Karuna Therapeutics Inc stock.

You can see the complete history of Ms. Olson stock trades at the bottom of the page.

Laurie Olson biography

Laurie J. Olson serves as Director of the Company. Ms. Olson is a seasoned pharmaceutical executive with more than 30 years of commercial and corporate strategy experience, most recently serving as the Executive Vice President, Strategy and Commercial Operations at Pfizer Inc. until 2018. In this role, Ms. Olson led a global organization accountable for corporate strategic planning, portfolio management, and commercial support functions. Ms. Olson served as a member of Pfizer's Portfolio Strategy and Investment Committee as well as the Pfizer Board of Directors' Science and Technology Committee, where she was accountable for informing therapeutic area strategies and the utilization of new technologies and analytic methods to drive R&D and commercial productivity. She also was a member of the Business Development, Disclosure, Diversity, and Compliance Committees where she supported Pfizer's commitment to maintaining its transparency and compliance with internal and external stakeholders. Prior to her role as Executive Vice President, Ms. Olson held various positions of increasing authority during her tenure at Pfizer from 1987 to 2018. She currently serves as a member of the Board of Trustees of the Mystic Seaport Museum in Mystic, Connecticut. Ms. Olson received a B.A. in Economics from State University of New York at Stony Brook and an M.B.A. in Marketing from Hofstra University.

What's Laurie Olson's mailing address?

Laurie's mailing address filed with the SEC is C/O QUANTERIX CORPORATION,, 900 MIDDLESEX TURNPIKE, BILLERICA, MA, 01821.

Insiders trading at Karuna Therapeutics Inc

Over the last 5 years, insiders at Karuna Therapeutics Inc have traded over $496,938,545 worth of Karuna Therapeutics Inc stock and bought 1,501,936 units worth $53,814,390 . The most active insiders traders include Health Llc Pure Tech, James Healy oraz Robert Nelsen. On average, Karuna Therapeutics Inc executives and independent directors trade stock every 12 days with the average trade being worth of $18,341,187. The most recent stock trade was executed by Stephen K. Brannan on 8 March 2024, trading 7,500 units of KRTX stock currently worth $636,600.

What does Karuna Therapeutics Inc do?

we are an innovative clinical-stage biopharmaceutical company primarily focused on developing novel therapies to address disabling neuropsychiatric conditions characterized by significant unmet medical need. our pipeline is built on the broad therapeutic potential of our lead product candidate, karxt, an oral modulator of muscarinic receptors that are located both in the central nervous system, or cns, and various peripheral tissues. karxt is our proprietary product candidate that combines xanomeline, a novel muscarinic agonist, with trospium, an approved muscarinic antagonist, to preferentially stimulate muscarinic receptors in the cns. we have assembled a team with extensive expertise in the research, development and commercialization of numerous cns agents, as well as deep familiarity with the biology of neuropsychiatric disorders, such as schizophrenia and ad, including the role of muscarinic receptors in their potential treatment. we will leverage this expertise to develop a pip

Complete history of Ms. Olson stock trades at Pfizer, Quanterix Corp oraz Karuna Therapeutics Inc

Karuna Therapeutics Inc executives and stock owners

Karuna Therapeutics Inc executives and other stock owners filed with the SEC include:

• Steven Paul,
  Chairman of the Board, President, Chief Executive Officer
• Andrew Miller,
  Chief Operating Officer
• Edmund Harrigan,
  Independent Director
• Troy Ignelzi,
  Chief Financial Officer
• Dr. Steven M. Paul M.D.,
  CEO, Pres & Chairman
• Dr. Andrew Craig Miller,
  Co-Founder & COO
• Dr. Stephen K. Brannan,
  Chief Medical Officer
• Dr. Troy A. Ignelzi,
  CFO & Sec.
• Stephen Brannan,
  Chief Medical Officer
• Atul Pande,
  Independent Director
• James Healy,
  Independent Director
• Jeffrey Jonas,
  Director
• Heather Preston,
  Independent Director
• Robert Nelsen,
  Independent Director
• Christopher Coughlin,
  Independent Director
• Laurie Olson,
  Director
• Giorgio Attardo,
  Vice President, CMC and Preclinical Development
• Dr. Ronald N. Marcus M.D.,
  Sr. VP of Medical
• Charmaine Lykins,
  Chief Commercial Officer
• Dr. James E. Audia Ph.D.,
  Head of Medicinal Chemistry & Sr. Adviser
• Dr. Alan Breier,
  Chair of Scientific Advisory Board & Chief Clinical Advisor
• Stephanie Moore,
  VP of HR
• Sharon Sawchak R.N.,
  VP of Clinical Operations & Compliance
• Mia Kelley J.D.,
  VP of Legal Affairs
• Jason Parker Brown,
  VP of Corp. Fin.
• Venture Partners Ix, Llcarc...,
  
• William Meury,
  President and CEO
• Bharat M Chowrira,
  Director
• Venture Partners Ix, Llcarc...,
  
• Charmaine Lykins,
  Chief Commercial Officer
• Health Llc Pure Tech,
  
• David E. Wheadon,
  
• Denice Torres,
  
• William P Jr Kane,
  Chief Commercial Officer
• Jason Parker Brown,
  Chief Financial Officer